149 related articles for article (PubMed ID: 25434451)
1. [A case of platinum-resistant, recurrent ovarian clear cell adenocarcinoma successfully treated with irinotecan (CPT-11) and paclitaxel (PTX) chemotherapy].
Konishi H; Takehara K; Okame S; Yamamoto Y; Kojima A; Shiroyama Y; Yokoyama T; Nogawa T
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1437-9. PubMed ID: 25434451
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
Ueda Y; Miyatake T; Nagamatsu M; Yamasaki M; Nishio Y; Yoshino K; Fujita M; Tsutsui T; Enomoto T; Kimura T
Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):259-63. PubMed ID: 23880598
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan hydrochloride (CPT-11) and cisplatin as first-line chemotherapy after initial surgery for ovarian clear cell adenocarcinoma.
Takakura S; Saito M; Ueda K; Motegi M; Takao M; Yamada K; Okamoto A; Niimi S; Sasaki H; Tanaka T; Ochiai K
Int Surg; 2007; 92(4):202-8. PubMed ID: 18050828
[TBL] [Abstract][Full Text] [Related]
4. Complete response to radiation therapy in a patient with chemotherapy-resistant ovarian clear cell adenocarcinoma.
Takai N; Utsunomiya H; Kawano Y; Nasu K; Narahara H; Miyakawa I
Arch Gynecol Obstet; 2002 Dec; 267(2):98-100. PubMed ID: 12439556
[TBL] [Abstract][Full Text] [Related]
5. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.
Takakura S; Takano M; Takahashi F; Saito T; Aoki D; Inaba N; Noda K; Sugiyama T; Ochiai K;
Int J Gynecol Cancer; 2010 Feb; 20(2):240-7. PubMed ID: 20169667
[TBL] [Abstract][Full Text] [Related]
7. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
8. [A case of advanced ovarian clear cell adenocarcinoma responding to cisplatin-cyclophosphamide and paclitaxel-carboplatin].
Iwasaki K; Komuro Y; Masumoto N; Asaoka K; Ishitani K
Gan To Kagaku Ryoho; 1999 Sep; 26(10):1483-6. PubMed ID: 10500539
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer.
Polyzos A; Kosmas C; Toufexi H; Malamos N; Lagadas A; Kosmidis C; Ginopoulos P; Ziras N; Kandilis K; Georgoulias V
Anticancer Res; 2005; 25(5):3559-64. PubMed ID: 16101180
[TBL] [Abstract][Full Text] [Related]
10. ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
Lee M; Kim SW; Nam EJ; Cho H; Kim JH; Kim YT; Kim S
Yonsei Med J; 2014 Nov; 55(6):1664-71. PubMed ID: 25323906
[TBL] [Abstract][Full Text] [Related]
11. [Paclitaxel + carboplatin (TC)-resistant stage Ic squamous cell carcinomas arising in mature cystic teratomas of the ovary].
Ishikawa M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Miyazaki K
Gan To Kagaku Ryoho; 2010 Apr; 37(4):747-52. PubMed ID: 20414041
[TBL] [Abstract][Full Text] [Related]
12. Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
Takano M; Sugiyama T; Yaegashi N; Suzuki M; Tsuda H; Sagae S; Udagawa Y; Kuzuya K; Kigawa J; Takeuchi S; Tsuda H; Moriya T; Kikuchi Y
Int J Clin Oncol; 2007 Aug; 12(4):256-60. PubMed ID: 17701003
[TBL] [Abstract][Full Text] [Related]
13. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
[TBL] [Abstract][Full Text] [Related]
14. [A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+cisplatin].
Takami M; Kita E; Kuwana Y; Ohta Y; Nakayama Y; Fukai H; Matsumoto H; Takimoto T; Ichikawa G; Yamamoto T
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1243-5. PubMed ID: 18633273
[TBL] [Abstract][Full Text] [Related]
15. [Chemotherapy for recurrent ovarian cancer].
Nishimura H; Imamura K; Chang C
Gan To Kagaku Ryoho; 1996 Aug; 23(9):1124-8. PubMed ID: 8751798
[TBL] [Abstract][Full Text] [Related]
16. [Colonic perforation in a patient treated with combination chemotherapy for recurrent ovarian clear cell adenocarcinoma].
Shitara K; Munakata M; Ishiguro A; Kudo T; Okada R; Tomioka R; Mitobe S; Yokoyama S; Sakata Y
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1497-1500. PubMed ID: 17033246
[TBL] [Abstract][Full Text] [Related]
17. [A recurrent ovarian cancer patient who achieved a complete response following irinotecan plus CDDP therapy].
Kawashima T; Murakami H; Kanamori T; Nakamura Y
Gan To Kagaku Ryoho; 2007 Mar; 34(3):461-3. PubMed ID: 17353644
[TBL] [Abstract][Full Text] [Related]
18. Case of pure ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin but responsive to monotherapy with weekly irinotecan.
Nakamura Y; Kamei T; Shinagawa M; Sakamoto Y; Miwa I
J Obstet Gynaecol Res; 2015 May; 41(5):809-12. PubMed ID: 25511544
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial.
Utsunomiya H; Akahira J; Tanno S; Moriya T; Toyoshima M; Niikura H; Ito K; Morimura Y; Watanabe Y; Yaegashi N
Int J Gynecol Cancer; 2006; 16(1):52-6. PubMed ID: 16445610
[TBL] [Abstract][Full Text] [Related]
20. Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9).
Esposito F; Cecere SC; Magazzino F; Katsaros D; Ottaiano A; Gadducci A; Pisano C; Scalone S; Rabaiotti E; Salutari V; Cormio G; Canuto EM; Greggi S; Savarese A; Marinaccio M; Scollo P; Santeufemia DA; Sacco C; Facchini G; Pignata S
Oncology; 2014; 86(5-6):351-8. PubMed ID: 24942520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
